Engitix
Rethinking Drug Discovery for Fibrosis and Cancer - To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $54.0m | Series A | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 73 % | - | - | 119 % | 58 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5 %) | (37 %) | - | (69 %) | (59 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (10 %) | (39 %) | - | (64 %) | (48 %) | (36 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 90 % | - | - | - | - | - |
Source: Company filings or news article
Related Content
Engitix is a biotechnology company focused on transforming drug discovery for fibrosis and cancer using its pioneering human extracellular matrix (ECM) based platform. The company operates in the life sciences market, specifically targeting pharmaceutical and biotechnology sectors. Engitix's core business model revolves around developing in vitro models that closely mimic the natural human cell environment, thereby increasing the accuracy and success rate of identifying new therapeutic targets and mechanisms of action. The company collaborates with pharmaceutical and biotech partners to maximize the potential of its discovery platform, creating a diversified portfolio of programs aimed at treating fibrosis and solid tumors. Revenue is generated through partnerships, licensing agreements, and potentially future product sales. Engitix's innovative approach aims to create a healthier future for patients with life-threatening diseases by improving the efficacy and success rate of drug discovery.
Keywords: ECM-based platform, drug discovery, fibrosis, cancer, in vitro models, therapeutic targets, biotech partnerships, pharmaceutical, life sciences, solid tumors.